Creo Medical Group PLC
AIM:CREO Stock Report
Creo Medical Group Past Earnings Performance Creo Medical Group's earnings have been declining at an average annual rate of -8.8%, while the Medical Equipment industry saw earnings growing at 1.9% annually. Revenues have been growing at an average rate of 38.3% per year.
Key information
-8.8%
Earnings growth rate
Medical Equipment Industry Growth -9.5% Revenue growth rate 38.3% Return on equity -47.3% Net Margin -73.9% Last Earnings Update 30 Jun 2024
Recent past performance updates
First half 2024 earnings released: UK£0.034 loss per share (vs UK£0.044 loss in 1H 2023) Oct 02
Full year 2023 earnings: EPS and revenues miss analyst expectations May 16
Creo Medical Group PLC to Report Fiscal Year 2023 Results on May 15, 2024 Apr 26
First half 2023 earnings released: UK£0.044 loss per share (vs UK£0.074 loss in 1H 2022) Sep 17
Creo Medical Group PLC to Report First Half, 2023 Results on Sep 12, 2023 Sep 05
Full year 2022 earnings: EPS misses analyst expectations Apr 27
Show all updates
New minor risk - Shareholder dilution Oct 27
Consensus EPS estimates fall by 24% Oct 25
Chairman recently bought UK£700k worth of stock Oct 25
Price target decreased by 28% to UK£0.57 Oct 24
New minor risk - Market cap size Oct 15
Consensus EPS estimates fall by 11% Oct 07
First half 2024 earnings released: UK£0.034 loss per share (vs UK£0.044 loss in 1H 2023) Oct 02
New minor risk - Shareholder dilution Oct 02
No longer forecast to breakeven Oct 01
New minor risk - Share price stability Sep 30 Micro-Tech (NL) International B.V. entered into a binding agreement to acquire 51% stake in Creo Medical, S.L.U. from Creo Medical Group PLC (AIM:CREO) for €36.7 million. Sep 20
Creo Medical Group PLC (LON:CREO) Screens Well But There Might Be A Catch Sep 19
New major risk - Financial position Sep 18
Creo Medical Group PLC, Annual General Meeting, Jun 26, 2024 Jun 02
Consensus EPS estimates fall by 21% May 22
Full year 2023 earnings: EPS and revenues miss analyst expectations May 16 Creo Medical Group plc Announces Board Changes May 15
Forecast to breakeven in 2026 May 07
New minor risk - Financial data availability May 03
Creo Medical Group PLC to Report Fiscal Year 2023 Results on May 15, 2024 Apr 26
New minor risk - Profitability Mar 11
Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower Mar 02
Creo Medical Group plc Announces Microwave Lung Ablation Update Mar 01
New minor risk - Share price stability Feb 07
Creo Medical Group plc Announces Continued Progress on the Phased Market Release of Its Latest Device, Speedboat® UltraSlim Feb 01
Forecast to breakeven in 2026 Dec 31
Revenues Tell The Story For Creo Medical Group PLC (LON:CREO) As Its Stock Soars 29% Dec 29
Creo Medical Group plc Announces First Use of Speedboat UltraSlim in the USA Dec 15
Creo Medical Group PLC Announces the Initiation of Its Commercial Launch of Speedboat Ultraslim Dec 13
Creo Medical Group plc Receives 510(K) Clearance from the Us Food & Drug Administration for Its Speedboat Ultraslim Device Nov 02
Creo Medical Group plc Announces EU Launch Accelerated by 18 Months Eu Regulatory Pathway for Launch Early 2024 Oct 26
Is Creo Medical Group (LON:CREO) Weighed On By Its Debt Load? Oct 06
First half 2023 earnings released: UK£0.044 loss per share (vs UK£0.074 loss in 1H 2022) Sep 17
Creo Medical Group PLC to Report First Half, 2023 Results on Sep 12, 2023 Sep 05
Creo Medical Group PLC, Annual General Meeting, Jun 27, 2023 May 27
Creo Medical Group plc Announces First In-Human Milestone Reaches for Microblate Flex as Part of Lung Tissue Ablation Clinical Study May 23
Full year 2022 earnings: EPS misses analyst expectations Apr 27
Key Executive recently bought UK£543k worth of stock Mar 15
Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023 Feb 18 Creo Medical Group PLC has completed a Follow-on Equity Offering in the amount of £28.5 million. Feb 17
Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023 Feb 16
Less than half of directors are independent Nov 16
Creo Medical Limited, Annual General Meeting, Jun 28, 2022 Jun 29
Creo Medical Limited to Report Fiscal Year 2021 Results on May 23, 2022 May 17
Less than half of directors are independent Apr 27
Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £5.06601 million. Sep 08
Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £31.250001 million. Aug 14
New 90-day high: UK£2.23 Feb 17
Creo Medical (LON:CREO) Is In A Good Position To Deliver On Growth Plans Feb 03
New 90-day high: UK£2.12 Jan 23
Creo Medical Group plc Receives US FDA clearance for MicroBlate™ Flex device Jan 08
How Many Creo Medical Limited (LON:CREO) Shares Do Institutions Own? Dec 09
New 90-day high: UK£2.08 Dec 09
New 90-day low: UK£1.67 Oct 13
First half earnings released Sep 29
New 90-day low: UK£1.72 Sep 19
Revenue & Expenses Breakdown
How Creo Medical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History AIM:CREO Revenue, expenses and earnings (GBP Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Jun 24 30 -22 41 0 31 Mar 24 31 -22 41 0 31 Dec 23 31 -22 41 0 30 Sep 23 30 -23 41 0 30 Jun 23 29 -25 42 0 31 Mar 23 28 -26 43 0 31 Dec 22 27 -27 44 0 30 Sep 22 27 -28 45 0 30 Jun 22 26 -28 47 0 31 Mar 22 26 -26 44 0 31 Dec 21 25 -25 42 0 30 Sep 21 24 -23 38 0 30 Jun 21 22 -21 34 0 31 Mar 21 16 -21 31 0 31 Dec 20 9 -20 28 0 30 Sep 20 5 -19 24 0 30 Jun 20 0 -17 20 0 31 Mar 20 0 -17 20 0 31 Dec 19 0 -16 19 0 30 Jun 19 0 -13 16 0 31 Mar 19 0 -12 14 0 31 Dec 18 0 -10 12 0 31 Dec 17 0 -8 10 0 30 Sep 17 0 -8 9 0 30 Jun 17 0 -8 8 0 30 Jun 16 1 -5 6 0 29 Feb 16 1 -3 4 0 28 Feb 15 0 -2 3 0 28 Feb 14 1 -2 3 0
Quality Earnings: CREO is currently unprofitable.
Growing Profit Margin: CREO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CREO is unprofitable, and losses have increased over the past 5 years at a rate of 8.8% per year.
Accelerating Growth: Unable to compare CREO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CREO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (39.9%).
Return on Equity
High ROE: CREO has a negative Return on Equity (-47.26%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
